Physician profile
Peter Wong
NPI 1750398277
$2,181.86
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $103 · 2021: $403 · 2023: $253 · 2024: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $481.48 | 2019-2024 | Wegovy, Saxenda |
| Astrazeneca Pharmaceuticals LP | $385.35 | 2019-2024 | Airsupra, Farxiga |
| Pfizer INC. | $184.51 | 2019-2021 | |
| Amgen INC. | $133.02 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $116.24 | 2020-2023 | Mounjaro |
| Abbvie INC. | $112.37 | 2019-2020 | |
| Allergan, INC. | $112.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.35 | 2019-2021 | |
| Insulet Corporation | $97.63 | 2019 | |
| Amarin Pharma, INC. | $71.77 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $50.72 | 2019 | |
| Dexcom, INC. | $48.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.96 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.52 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $24.04 | 2021 | |
| Esperion Therapeutics, INC. | $18.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.79 | 2021 | |
| Glaxosmithkline, LLC. | $15.18 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.19 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.80 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $12.63 | 2019 | |
| Aytu Biopharma, INC. | $12.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.